×

Hedge Funds Carl Icahn

  • Chief Executive Officer Peter Hancock announced on March 9 that he would depart once the board found a replacement, citing a lack of confidence among directors and investors. Chairman Douglas Steenland has said that AIG's board remains committed to the existing turnaround effort, but analysts are doubtful over whether a new CEO would carry out Hancock's...

  • Chief Executive Officer Peter Hancock announced on March 9 that he would depart once the board found a replacement, citing a lack of confidence among directors and investors. Chairman Douglas Steenland has said that AIG's board remains committed to the existing turnaround effort, but analysts are doubtful over whether a new CEO would carry out Hancock's...

  • Chief Executive Officer Peter Hancock announced on March 9 that he would depart once the board found a replacement, citing a lack of confidence among directors and investors. Chairman Douglas Steenland has said that AIG's board remains committed to the existing turnaround effort, but analysts are doubtful over whether a new CEO would carry out Hancock's...

  • NEW YORK, May 1- Carl Icahn's big bet on falling prices for biofuels credits generated a rare profit in that area last quarter for the billionaire investor's refining company CVR Energy, according to public filings. CVR Energy's refining unit posted a net gain of $6.4 million associated with the credits, a $50 million turnaround from the year-ago period when CVR...

  • NEW YORK, April 27- Strong growth from Bristol-Myers Squibb Co's Opdivo and Yervoy cancer immunotherapies drove the company's first-quarter results past analysts' expectations and relieved some anxiety about increasing competition for the drugs. "Sales for Opdivo were strong despite a more competitive landscape," Chief Executive Officer Giovanni...

  • NEW YORK, April 27- Bristol-Myers Squibb Co on Thursday reported higher-than-expected quarterly earnings, helped by increased sales of cancer drugs Opdivo and Yervoy and blood thinner Eliquis. Bristol-Myers shares were up 1.9 percent at $54.80 on the New York Stock Exchange. Bristol-Myers reported a profit of $1.57 billion, or 94 cents a share, for the quarter,...

  • NEW YORK, April 27- Bristol-Myers Squibb Co on Thursday posted better-than-expected first-quarter earnings, helped by growth from cancer drugs Opdivo and Yervoy and blood thinner Eliquis. Bristol-Myers reported profit of $1.57 billion, or 94 cents a share, in the quarter, up from $1.20 billion, or 71 cents a share, a year earlier. Wall Street analysts, on average,...

  • In one example of a change in strategy, Neuberger Berman sounded out hedge funds about investing in Whole Foods Market and pressing for change.

  • Brian Duperreault

    Shares of AIG spiked after a Bloomberg report said the insurer is considering Hamilton Insurance's Brian Duperreault to be CEO.

  • Tony Robbins

    Carl Icahn, Warren Buffett, Ray Dalio, John Bogle and others exhibit these traits.

  • Mary Barra (2ndL), CEO of General Motors, Gary Cohn (2ndR), President of President of Goldman Sachs, and Doug McMillon (R), CEO of Walmart, listen while US President Donald Trump speaks before a policy and strategy forum with executives in the State Dining Room of the White House February 3, 2017 in Washington, DC.

    Top aide Gary Cohn is muscling aside some of President Donald Trump's hard-right advisers to push more moderate, business-friendly economic policies.

  • WASHINGTON/ BOSTON, April 16- In a White House marked by infighting, top economic aide Gary Cohn, a Democrat and former Goldman Sachs banker, is muscling aside some of President Donald Trump's hard-right advisers to push more moderate, business-friendly economic policies. More than half a dozen sources on Wall Street and in the White House said Cohn has gained the...

  • WASHINGTON/ BOSTON, April 16- In a White House marked by infighting, top economic aide Gary Cohn, a Democrat and former Goldman Sachs banker, is muscling aside some of President Donald Trump's hard-right advisers to push more moderate, business-friendly economic policies. More than half a dozen sources on Wall Street and in the White House said Cohn has gained the...

  • April 13- American International Group Inc's board of directors declined to award Chief Executive Officer Peter Hancock a cash bonus for his work last year, after the company's dismal financial performance roiled shareholders, according to a proxy filing on Thursday. The figure includes his $1.6 million base salary, longer-term incentive pay in stock worth...

  • April 13- Drug company Innoviva Inc said on Thursday it would undertake a review of its costs, including executive compensation following pressure from activist investor Sarissa Capital Management LP. The news comes two weeks after hedge fund Sarissa Capital called for a sharp cut in the compensation of Innoviva's chief executive and the board.

  • April 13- Drug company Innoviva Inc said on Thursday it would undertake a review of its costs, including executive compensation following pressure from activist investor Sarissa Capital Management LP. The news comes two weeks after hedge fund Sarissa Capital called for a sharp cut in the compensation of Innoviva's chief executive and the board.

  • April 13- American International Group Inc's board of directors declined to award Chief Executive Officer Peter Hancock a cash bonus for his work last year, after the company's dismal financial performance roiled shareholders, according to a proxy filing on Thursday. Hancock did, however, receive his $1.6 million base salary and longer-term incentive pay in...

  • Peter Hancock, chief executive officer of American International Group

    American International Group's board of directors declined to award CEO Peter Hancock a cash bonus for his work last year.

  • board of directors declined to award Chief Executive Officer Peter Hancock a cash bonus for his work last year, after the company's dismal financial performance roiled shareholders, according to a proxy filing on Thursday. The insurance company's board has also re-nominated Samuel Merksamer, who represents billionaire Carl Icahn, to serve on the board for...

  • *To get $300 mln from Biogen, $170 mln from Roche upfront. April 13- Bristol-Myers Squibb Co said on Thursday it would license two of its drugs to Biogen Inc and Roche Holding AG for an upfront fee of $470 million. The Wall Street Journal reported in February that billionaire investor Carl Icahn had taken a stake in Bristol and saw the company as a possible takeover...